Cidara Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Cidara Therapeutics es Jeff Stein , nombrado en Jan 2014, tiene una permanencia de 10.83 años. compensación anual total es $1.56M, compuesta por 38.1% salario y 61.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.03% de las acciones de la empresa, por valor de $1.48M. La antigüedad media del equipo directivo y de la junta directiva es de 3.5 años y 3.8 años, respectivamente.
Información clave
Jeff Stein
Chief Executive Officer (CEO)
US$1.6m
Compensación total
| Porcentaje del salario del CEO | 38.1% |
| Permanencia del CEO | 10.8yrs |
| Participación del CEO | 1.0% |
| Permanencia media de la dirección | 3.5yrs |
| Promedio de permanencia en la Junta Directiva | 3.8yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth
Sep 28
Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop
Apr 17Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year
Mar 25We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely
Mar 14Cidara spikes on $11M milestone payment from partner Mundipharma
Oct 04Cidara begins dosing of antiviral CD388 in trial for preventing influenza
Sep 13Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M
Aug 09Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts
Dec 17Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic
Aug 17Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?
Aug 04Cidara Therapeutics: Rezafungin Data Could Bring Value
Jul 20Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$112m |
| Mar 31 2024 | n/a | n/a | -US$24m |
| Dec 31 2023 | US$2m | US$594k | -US$23m |
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$22m |
| Dec 31 2022 | US$1m | US$566k | -US$34m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$2m | US$566k | -US$42m |
| Sep 30 2021 | n/a | n/a | -US$47m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$74m |
| Dec 31 2020 | US$1m | US$542k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$47m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$1m | US$526k | -US$41m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$69m |
| Dec 31 2018 | US$1m | US$501k | -US$69m |
| Sep 30 2018 | n/a | n/a | -US$70m |
| Jun 30 2018 | n/a | n/a | -US$69m |
| Mar 31 2018 | n/a | n/a | -US$59m |
| Dec 31 2017 | US$2m | US$460k | -US$56m |
Compensación vs. Mercado: La compensación total de Jeff($USD1.56M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD647.72K).
Compensación vs. Ingresos: La compensación de Jeff ha aumentado mientras la empresa no es rentable.
CEO
Jeff Stein (69 yo)
10.8yrs
Permanencia
US$1,558,544
Compensación
Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 10.8yrs | US$1.56m | 1.03% $ 1.5m | |
| COO & Corporate Secretary | 3.3yrs | US$929.86k | 0.073% $ 104.8k | |
| Chief Medical Officer | 8.2yrs | US$884.09k | 0.18% $ 261.1k | |
| Founder & Chief Strategy Officer | no data | US$613.24k | sin datos | |
| CFO & Principal Accounting Officer | 3.2yrs | US$683.71k | 0.11% $ 153.3k | |
| Senior Vice President of People & Culture | 3.8yrs | sin datos | sin datos | |
| Chief Scientific Officer | 5.7yrs | US$1.39m | 0.12% $ 171.9k | |
| Senior VP of Translational Research & Development | 1.3yrs | sin datos | sin datos | |
| Chief Business Officer | less than a year | sin datos | sin datos |
3.5yrs
Permanencia media
51.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CDTX se considera experimentado (3.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 10.8yrs | US$1.56m | 1.03% $ 1.5m | |
| Independent Chairman of the Board | 10.6yrs | US$126.84k | 0.0021% $ 3.1k | |
| Independent Director | 10.6yrs | US$98.84k | 0% $ 0 | |
| Member of the Scientific Advisory Board | 4.3yrs | sin datos | sin datos | |
| Independent Director | 3.8yrs | US$86.84k | 0.00021% $ 301.9 | |
| Independent Director | 3.8yrs | US$82.34k | 0% $ 0 | |
| Independent Director | 6.7yrs | US$91.34k | 0% $ 0 | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Director | less than a year | sin datos | sin datos | |
| Member of Scientific Advisory Board | less than a year | sin datos | sin datos | |
| Member of Scientific Advisory Board | less than a year | sin datos | sin datos |
3.8yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de CDTX se considera experimentada (3.8 años de antigüedad promedio).